Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer

Journal of Urology

Volumn 167, Issue 2 I, 2002, Pages 512-515

  Isshiki, Shinzou ^a   Akakura, Koihiro ^a   Komiya, Akira ^a   Suzuki, Hiroyoshi ^a   Kamiya, Naoto ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Chromogranins; Prostate; Prostate specific antigen; Prostatic neoplasms; Tumor markers, biological

Indexed keywords

ANDROGEN; CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; RELIABILITY; TREATMENT OUTCOME;

EID: 0036141890     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-200202000-00014     Document Type: Article

References (20)

1. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration
2. Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains
3. Peptide-hormone and serotonin-immunoreactive cells reactive in normal and hyperplastic prostate glands
4. The course of neuroendocrine differentiation in prostatic carcinomas
5. The endocrine component of prostate carcinomas, mixed adenocarcinoma-carcinoid tumors and non-tumor prostate. Histochemical and ultrastructual identification of the endocrine cells
6. Neuroendocrine differentiation in prostate carcinoma
7. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study
8. Secretions of chromogranin A by peptide-producing endocrine neoplasms
9. Hormone-negative chromogranin A-positive endocrine tumors
10. Neuroendocrine differentiation in prostatic malignancy
11. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients
12. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
13. Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones
14. Elevated plasma chromogranin-A concentrations in prostatic carcinoma
15. Neuroendocrine differentiation in carcinomas of prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?
16. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of prostate
17. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy
18. Characterization of neuroendocrine differentiation in human benign prostate and prostate adenocarcinoma
19. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status
20. Do neuroendocrine cells in human prostate cancer express androgen receptor?